Revolution Medicines, Inc.
RVMD
Rangering i aksjer
#578
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Aksjekurs
$196.75
Markedsverdi
$42.17B
Endring (1 dag)
0.10%
Endring (1 år)
267.82%
Land
US
Handel Revolution Medicines, Inc. (RVMD)
Kategori
Healthcare
Inntekter for Revolution Medicines, Inc. (RVMD)
Inntekter i Jun 2026 TTM: 0.00
Ifølge de nyeste økonomiske rapportene til Revolution Medicines, Inc. er selskapets nåværende inntekter (TTM) 0.00. I 2023 hadde selskapet inntekter på $11.58M en nedgang sammenlignet med inntektene i 2022, som var $35.38M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Revolution Medicines, Inc. fra 2017 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | -100.00% |
| 2023 | $11.58M | -67.27% |
| 2022 | $35.38M | 20.38% |
| 2021 | $29.39M | -31.62% |
| 2020 | $42.98M | -14.10% |
| 2019 | $50.04M | 148.16% |
| 2018 | $20.17M | 0.00% |
| 2017 | 0.00 | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
